Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome

Pediatric Rheumatology

Volumn 9, Issue , 2011, Pages

  Shigemura, Tomonari ^a   Yamazaki, Takashi ^a   Hara, Yosuke ^a   Ou, Jing Ni ^b   Stevens, Anne M ^b   Ochs, Hans D ^b   Koike, Kenichi ^a   Agematsu, Kazunaga ^c  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^c SHINSHU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; C REACTIVE PROTEIN; CYCLOSPORIN A; FERRITIN; IBUPROFEN; INTERLEUKIN 18; LACTATE DEHYDROGENASE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE;

ARTICLE; CASE REPORT; DRUG DOSE REDUCTION; ERYTHROPHAGOCYTOSIS; FEMALE; FEVER; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; MACROPHAGE ACTIVATION SYNDROME; PRIORITY JOURNAL; RASH;

EID: 79960113614     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/1546-0096-9-15     Document Type: Article

References (14)

1. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007, 369:767-778. 10.1016/S0140-6736(07)60363-8, 17336654.
2. Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, Viola S, Martini A. Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Journal of Pediatrics 2005, 146:598-604. 10.1016/j.jpeds.2004.12.016, 15870661.
3. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K. Cloning of a new cytokine that induces IFN-g production by T cells. Nature 1995, 78:88-91.
4. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. Journal of Leukocyte Biology 2003, 73:213-224. 10.1189/jlb.0602313, 12554798.
5. Yoshimoto T, Takeda H, Tanaka T, Ohkusu K, Kawashima S, Okamura H, Akira S, Nakanishi K. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells and B cells: synergism with IL-18 for IFN-gamma production. J Immunol 1998, 161:3400-3407.
6. Maeno N, Takei S, Nomura Y, Imanaka H, Hokonohara M, Miyata K. Highly elevated serum levels of interleukin-18 in systemic juvenile idiopathic arthritis but not in other juvenile idiopathic arthritis subtypes or in Kawasaki disease. Arthritis Rheum 2002, 46:2539-2541. comment on the article by Kawashima et al, 10.1002/art.10389, 12355506.
7. Shimizu M, Yokoyama T, Yamada K, Kaneda H, Wada H, Wada T, Toma T, Ohta K, Kasahara Y, Yachie A. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology 2010, 49:1645-1653. 10.1093/rheumatology/keq133, 20472718.
8. Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Archives of Disease in Childhood 2001, 85:421-426. 10.1136/adc.85.5.421, 1718981, 11668110.
9. Bleesing J, Prada A, Siegel DM, Villanueva J, Olson J, Ilowite NT, Brunner HI, Griffin T, Graham TB, Sherry DD, Passo MH, Ramanan AV, Filipovich A, Grom AA. The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum 2007, 56:965-971. 10.1002/art.22416, 17328073.
10. Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, Ramanan AV. Anakinra treatment for systemic onset juvenile idiopathic arthritis. Rheumatology 2008, 47:555-556.
11. Behrens EM, Beukelman T, Paessler M, Cron RQ. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol 2007, 34:1133-811.
12. Woo P, Wilkinson N, Prieur AM, Southwood T, Leone V, Livermore P, Wythe H, Thomson D, Kishimoto T. Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement. Arthritis Res Ther 2005, 7:1281-1288.
13. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC. Anakinra as first-line disease modifying therapy in systemic juvenile idiopathic arthritis. Arthritis and Rheumatism 2010, 63:45-555.
14. Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology 2011, 50:417-419. 10.1093/rheumatology/keq218, 20693540.